Medical Research News

Nursing

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cunnington M et al. – The risk of all major birth defects following first–trimester exposure to sumatriptan was 4.6% (95% CI 2.9–7.2%). This coupled with a consistent failure of additional epidemiological studies to observe a signal for major teratogenicity gives a level of reassurance concerning the safety of sumatriptan in pregnancy. There are too few data on naratriptan to draw definitive conclusions, and the sample size for sumatriptan remains too small to detect any but very large increases in specific birth defects.

Related Articles

Embryonic development and pregnancy test sensitivity: the importance of earlier pregnancy detection
Women's Health, 11/04/09    Relevance Score: 48%

Trauma in Pregnancy
American Journal of Nursing, 11/10/09    Relevance Score: 46%

Medical treatments for idiopathic thrombocytopenic purpura during pregnancy
Cochrane Reviews, 10/27/09    Relevance Score: 46%

Sexuality During Pregnancy
The Journal of Sexual Medicine, 10/23/09    Relevance Score: 46%

Routine pre-pregnancy health promotion for improving pregnancy outcomes
Cochrane Reviews, 10/22/09    Relevance Score: 46%

Today in Clinical Pharmacology...keeping you current

Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09

Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Pediatrics, 12/11/09

Emerging technologies in the delivery of erythropoietin for therapeutics
Medicinal Research Reviews, 12/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address